Thymosin Alpha-1 (Zadaxin)
The most clinically validated immunomodulatory peptide, approved in 35+ countries for hepatitis, sepsis, and immune deficiency.
Thymosin Alpha-1 (Tα1, Zadaxin) is a 28-amino acid peptide naturally produced by the thymus gland, first isolated and characterized by Dr. Allan Goldstein in the 1970s. It is the most extensively studied and clinically validated immunomodulatory peptide in the world, with regulatory approval in over 35 countries for the treatment of hepatitis B, hepatitis C, and various immune deficiency conditions. Tα1 is the primary active component of thymosin fraction 5, the thymic extract that was found to restore immune function in thymectomized animals. It has been studied in over 100 clinical trials covering hepatitis, cancer, sepsis, COVID-19, and vaccine adjuvancy. In the COVID-19 pandemic, Tα1 demonstrated significant reductions in mortality and ICU admission in multiple studies from China and Italy. Its broad immunomodulatory effects — enhancing both innate and adaptive immunity while also having anti-inflammatory properties — make it uniquely valuable for conditions involving immune dysregulation.
* Benefits based on preclinical/animal research unless otherwise noted.
Members-Only Access
Access advanced peptide education, protocol insights, and research-based information curated for informed users. Create a free account or log in to continue.
Please acknowledge the disclaimer above to continue.